- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Discusses SGLT2 Inhibitor Uptake Among Cardiologists, Nephrologists
As time goes on, we're finding out more and more benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors, said Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association.
Transcript
In the past decade, we’ve seen the SGLT2 class burst on to the scene, first in type 2 diabetes, and now in heart failure and renal disease. Are you seeing more patients with type 2 diabetes being prescribed these therapies by a cardiologist or nephrologist?
SGLT2 medications have really been a game changer in the world of diabetes, and we're finding out more and more benefits. As you know, this started off as a story about cardiovascular disease, it's now extended to renal disease. One initiative that the American Diabetes Association is leading in collaboration with the American Heart Association, is a program called No Diabetes by Heart. That effort, that has been a 3-year activity by us, aimed at consumers in general, at people with diabetes and at providers and health systems, has been moving the needle. We've done some recent survey data across the country that indicates that, particularly to the target providers that we've been looking at, and that is cardiologists and nephrologists, are more confident and more knowledgeable about these medications, and now increasingly view this as their responsibility to prescribe these medications. So we are seeing progress, but we still have further to go.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
